NASDAQ · Drug Manufacturers - Specialty & Generic
PCRX (PCRX) Stock
$25.02
-2.19%
NASDAQ: PCRX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
PCRX: Lowering target price to $26.00
Argus Research · Jul 15, 2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Jul 8, 2026
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare
Zacks · Jul 2, 2026
Zimmer Biomet (ZBH) Is Buying Pacira’s Iovera Device And Expanding Into Spasticity
Simply Wall St. · Jul 2, 2026
Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday
MT Newswires · Jul 1, 2026
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About PCRX
PCRX is led by CEO Frank D. Lee, employs 788 people, headquartered in US, publicly traded since 2011.
PCRX stock trades at $25.02 with a market capitalization of $984.16M. The stock is valued at a price-to-earnings (P/E) ratio of 178.08, price-to-book of 1.37, price-to-sales of 1.23. Over the past 52 weeks the stock has ranged between $18.80 and $27.64, and currently trades 9.5% below its 52-week high.
On profitability, PCRX generates a return on equity (ROE) of 71.00% — well above the market average, a sign of a high-quality business, return on capital employed of 4.76%, an operating margin of 4.55%, a net profit margin of 0.70%.